Vernalis shares slide after FDA turn thumbs down on their latest XR cold med
Five years ago Vernalis and Tris Pharma came up with a plan to develop a portfolio of branded cold meds, using Tris’ extended-release tech to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
